Top of this page
Skip navigation, go straight to the content

Our Company Magazine Detail

UCB leads Life Science event during Belgian Royal visit to China

  • Posted by

    UCB's record of helping Chinese patients goes back to the 1990s and we have plans for the future.

    That is why we are so proud to have led a life science event during this week's Belgian Royal visit to China (20 – 28 June). The visit will take place in Wuhan, Beijing, Shanghai, Suzhou and Shenzhen.

    The life science event, led by UCB CEO Jean-Christophe Tellier, brought together key academic, industry and government officials and comes as our company continues to reinforce its presence in China.

    Speakers included the Chinese Vice-Minister of National Health and Family Planning Commission Mr. Sun Zhigang as well as the Belgian Secretary of State for Foreign Trade Mr Pieter De Crem. The event explored ways to enhance synergies between Belgian and Chinese healthcare organisations and to increase the value they can bring to patients.

    UCB's presence in China can be traced by to the early 1990s. The launch in 2007 of our blockbuster treatment for patients suffering from epilepsy was an important landmark in establishing the company's reputation as a leader in neurology.

    Last year, UCB inaugurated a new state of the art 13,000 m² manufacturing site in Zhuhai which is playing a key role in UCB’s development in China. It will also support UCB’s growth strategy in the coming years in the Asia-Pacific region.

    Our commitment to China is deepening. Phase III clinical trials on two of our core neurology products have recently been published, opening up the possibility that patients in China will have access to their medicines in the years ahead.

    UCB has also been working to support awareness-raising initiatives in China and has developed strong relationships with medical and scientific associations in China.

    The week's Royal visit is a recognition of the importance of the Chinese economy and UCB's involvement demonstrates our long-term connection to healthcare in China.

    Tags:
    Categories:
    Share:

Leave a Comment